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The enthusiasm surrounding the clinical potential of embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) is tempered by the fact that key issues regarding their safety, efficacy, and long-termbene-
fits have thus far been suboptimal. Small molecules can potentially relieve these problems at major junctions
of stem cell biology and regenerative therapy. In this reviewwewill introduce recent advances in these impor-
tant areas and the first generation of small molecules used in the regenerative context. Current chemical
biology studies will provide the archetype for future interdisciplinary collaborations and improve clinical
benefits of cell-based therapies.Promise and Challenges for Regenerative Medicine
Life expectancy has increased dramatically in the modern era.
Along with it, there is the observed increase in chronic diseases
such as heart disease, neurodegenerative disorders, and
diabetes. These progressively degenerative conditions are
largely irreversible and incurable, except for rare cases where
organ transplantation is an option. The recognizable need to
correct or replace defective and failing tissues has led to
a surging interest in cell-based regenerative therapy. The main
goal is to produce a reliable source of replacement biomaterials
and tissues ex vivo and supplant the current donor-based
system, which is always in limited supply. Furthermore, an
ex vivo source can potentially be tailored to specific individuals,
which may prevent rejection due to donor-recipient incom-
patibility and the accompanying risks of immunosuppressive
drugs, which are necessary components of organ and tissue
transplant procedures (Teo and Vallier, 2010; Rolletschek and
Wobus, 2009).
Cell-based therapy has been used as a blanket term that
encompasses the usage of significantly different varieties of
pluripotent cells. Each variation possesses unique properties
that are not fully characterized and has different implications
under each therapeutic context. The establishment of in vitro
cultures of mouse embryonic stem cells (mESCs) (Evans and
Kaufman, 1981), human embryonic stem cells (hESCs) (Thom-
son et al., 1998), inducible pluripotent stem cells (iPSCs)
(Takahashi and Yamanaka, 2006), and the discovery of adult
somatic stem cells in various tissues initiated a flurry of studies
into their respective therapeutic potential for basic research
and for cell replacement (Figure 1). Recent characterization of
different pluripotency states put forth intriguing possibilities for
further refining lineage specification and increasing their utility
(Brons et al., 2007; Bao et al., 2009).
The initial body of research revealed a number of technical
obstacles against the practical usage of embryonic and induced
pluripotent cell types. The most pressing challenges are: devel-Chemistry & Boping a stable and renewable source of pluripotent cells, reliably
maintaining pluripotency without compromising genomic integ-
rity, and efficiently directing differentiation to eliminate cellular
heterogeneity. Guiding cell fate determination is especially
important because it relates directly to the feasibility and safety
of exogenous cell transplants. This is because undifferentiated
cells can spontaneously differentiate and result in tumor forma-
tion (Cooke et al., 2006; Blum and Benvenisty, 2008). It is also
obvious that established methods are inadequate due to the
inconsistent and haphazard nature of current maintenance and
directed differentiation approaches (Nagy et al., 1993; Reubinoff
et al., 2000). For example mESCs require the addition of
leukemia inhibitory factor (LIF) in themedium tomaintain pluripo-
tency and cell proliferation. By contrast, hESCs do not respond
to LIF but, instead, require transforming growth factor
b (TGF-b)/nodal and basic fibroblast growth factor (bFGF) in
the medium to sustain pluripotency (Vallier et al., 2005). Another
problem is the reliance of growth factors from feeder layers or
animal-derived serums in culture protocols, which inevitably
introduces batch variability. In addition the high costs of growth
factor additives are prohibitive to the large-scale production of
pluripotent cells and further limit clinical applications.
A potential alternative source of pluripotent cells is to repro-
gram differentiated somatic cell types to a pluripotent state.
There are two practical advantages to this approach: (1) it
circumvents ethical concerns of using embryo-derived stem
cells, and (2) it employs a patient’s own cells and would limit
immune rejection. A landmark study from Takahashi and Yama-
naka (2006) identified four transcription factors (Sox2, Oct4, Klf4,
and c-Myc) that, when introduced via viral-mediated transduc-
tion, reestablished pluripotency in adult fibroblasts. The resulted
iPSCs were shown to closely resemble ESCs because they were
pluripotent and could be induced to differentiate into every cell
type (Takahashi and Yamanaka, 2006; Yu et al., 2007). It has
since been reported that another combination of genetic factors
(Sox2, Oct4, Lin28, and Nanog) can also induce pluripotencyiology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 413
Figure 1. Applications of Small Molecules in
Cell-Based Therapies
Small molecules can intervene at many junctions of
the stepwise differentiation process. They can: (1)
promote self-renewal in culture, (2) enhance re-
programming of adult somatic cells, and (3) direct
differentiation of pluripotent or lineage-committed
progenitor cells. These features will be valuable for
harnessing the full potential of pluripotent cells in
regenerative therapy.
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2008). Although these results are exciting, some major issues
must be resolved before iPSCs become a viable option for cell
replacement therapy. The first is the introduction of reprogram-
ming factors using viral transduction systems, which raise
reasonable concerns for oncogenic risks in patients. This issue
has been partly addressedwith the availability of plasmid-based,
protein-based, andmodified RNA-based strategies that have re-
sulted in successful virus-free cellular reprogramming (Cho et al.,
2010; Okita et al., 2008; Warren et al., 2010). The second issue is
the extremely low reprogramming efficiency of 0.001%–0.005%
(Hasegawa et al., 2010), which remains unresolved because re-
programming mechanisms are imperfectly understood.
Endogenous somatic stem cells have been scrutinized as an
alternative to ex vivo sources. They are resident pools of
lineage-restricted multipotent cells that are responsible for
tissue turnover, and have been identified in the brain (Doetsch,
2003), skin (Jones and Watt, 1993), heart (Messina et al.,
2004), skeletal muscle (Martin et al., 2006), and intestines (Casali
and Batlle, 2009). They are a tempting source because it is theo-
retically possible to direct them toward tissue repair, all without
risking immunological incompatibility problems. However, they
are currently on the fringes of therapeutic options because their
isolation, propagation, and usage are unrefined and may be
restricted to local niches.
Another concern for cell-based therapies is posttransplanta-
tion events. The capacity of exogenous cells to integrate with
host tissue and restore normal physiological functions is low
using current methods. Although free floating, suspension cells
like bone marrow-derived hematopoietic stem cells (HSCs) are
less resistant to integration; the actual integration rate is highly
dependent on the stage of HSC differentiation and its affinity
for the local microenvironment (Lo Celso et al., 2009). The situa-
tion is more complicated when stem cells are introduced to414 Chemistry & Biology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reservedhighly structured organs like the heart,
where synchronous contractions are
crucial for function. Implanted cells either
die of the initial onslaught of inflammatory
cytokines or fail to integrate into the host
tissue; instead, establishing themselves
as a separate or hybrid entity at the trans-
plant site (Reinecke et al., 1999; Alvarez-
Dolado et al., 2003). Furthermore, the
impact of paracrine cell signaling cannot
be understated. Initial benefits described
from transplantation studies using various
sources of stem cells including bone
marrow, mesenchymal, and neural stemcells offered temporary functional improvements. These benefits
were subsequently characterized as the result of paracrine
factors secreted by the stem cells rather than true cell autono-
mous repair (Kim et al., 2010a; Perez-Ilzarbe et al., 2008).
Future technologies must take advantage of the synergistic
interactions between the transplanted cells and the local micro-
environment in order to harness the full potential of regenerative
therapy. Advances in chemical biology can conceivably serve
first as a tool to dissect the complicated pathways regulating
self-renewal and cell fate decisions, and second as the means
to manipulate those same pathways for the desired therapeutic
outcome.
Chemical Biology: Advantages of Small Molecules
The guiding principal in chemical biology is to discover and
develop synthetic bioactive molecules. It presents several
advantages over traditional protein- or gene-based tools. The
usage of traditional biomolecules is limited because they are
difficult to produce and manipulate. Their effects are unstable
and cannot be fine-tuned because genetic switches are gener-
ally all or none. They can modulate only a single target at
a time, and introduction of multiple biomolecules into a specific
tissue is technically challenging. In contrast, small molecules can
be delivered efficiently into the cell, can be targeted to specific
tissues, and their effects are reversible. The dosage of the
compounds can be modulated for maximum benefit, and
individual molecules can be furthermodified viamedicinal chem-
istry to increase potency, safety, or stability. Small molecules
can target the biology of a desired phenotype by stimulating
multiple druggable categories via intersecting signaling nodes.
Small molecules are also relatively inexpensive to produce and
can be scaled to particular needs. These attributes place small
molecules in a favorable position for regenerative medicine
developments.
Figure 2. Strategies for High-Throughput
Chemical Screening
Small molecules from a chemical library are iden-
tified in high-throughput screening assays using
stem cells. Compounds are evaluated for the
desired effects using cellular images, specific
promoter-driven reporters, or organism pheno-
types as readout.
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erative medicine because many key cellular events utilize the
same pathways and form druggable nodes. These key pathways
are Hedgehog (Hh), Wnt, TGF-b, Notch, and fibroblast growth
factor (FGF) (Jiang and Hui, 2008; MacDonald et al., 2009; Wu
and Hill, 2009; Bolo´s et al., 2007; Beenken and Mohammadi,
2009). Specific information on how these key pathways function
in pluripotency and differentiation is discussed in other excellent
reviews (Loebel et al., 2003; Pera and Tam, 2010). Furthermore,
small molecules have been identified that target these pathways
singly and in combination with other small molecules or genetic
factors. As an emerging area of study, small molecules have
provided early proof that cell fate is dynamic and can be manip-
ulated using artificial means. The attributes of pluripotent and
lineage-restricted progenitor cells, when combined with the
practical utility of small molecules, are powerful assets for real-
izing the full potential of regenerative therapy.
Small Molecules in Regenerative Medicine
Many small molecules relevant to stem cell biology were identi-
fied from chemical libraries using high-throughput cell pheno-
type-based, reporter-based, or organism-based screens
(Figure 2). Lead compounds were further examined to identify
associated targets and relevant pathways, which then guide
future optimization based on biochemical, pharmacological,
and physiological requirements (Ding and Schultz, 2004).
Compounds that promote self-renewal, facilitate reprogram-
ming, and direct differentiation pathways have been identified
using the above methods. These chemical biology discoveries,
detailed below, are shaping the future of regenerative medicine.
Self-Renewal and Pluripotency
A major obstacle for the practical usage of stem cells has been
maintaining their pluripotent state in culture. SpontaneousChemistry & Biology 18, April 22, 2011differentiation occurs due to constant
bombardment from undefined and varied
amounts of growth factors found in
traditional culture protocols that use
animal serum and feeder cells. For this
reason a number of serum- and feeder-
free protocols have been developed that
use commercially available supplements.
Many of these supplements still use
animal-derived and recombinant growth
factors, but they are optimized for
pluripotent cell culture and reduce batch
variability. They include KnockOut (Cheng
et al., 2004) or N2 and B27 (N2B27) (Ying
and Smith, 2003) that consist of essential
recombinant growth factors for mESCsand iPSCs using GIBCO’s proprietary formula. Another formula-
tion is to add LIF and bone morphogenetic protein (BMP) to
N2B27 media, which also drive continuous self-renewal in
serum-free conditions (Nichols and Ying, 2006). A feeder-free,
serum-free method has successfully maintained hESCs and
iPSCs in culture (Ludwig et al., 2006). It replaces the feeder layer
with an animal-derived extracellular matrix called Matrigel
(BD Bioscience), and a serum-free medium called mTeSR1
(STEMCELL Technologies) supplemented with recombinant
proteins (Ludwig et al., 2006). As promising as these new
feeder-free, serum-free approaches are, they are not yet
compatible with wide-scale clinical applications because
they still require complex animal-derived products or re-
combinant protein modulators, which can be expensive and
unstable.
The aforementioned issues motivate the development of
synthetic media formulations to minimize reliance on animal-
derived or recombinant bioactive products. The first-generation
collection of small molecules has been identified for this
purpose. Pluripotin (Table 1) was the first compound identified
in a chemical screen that propagates mESCs in an undifferenti-
ated state (Chen et al., 2006). This discovery was especially
remarkable because it showed that pluripotent cells can indeed
be maintained in chemically defined conditions, without the use
of animal-derived products or LIF. Furthermore, pluripotin did
not stimulate the predicted pluripotency pathways, i.e.,
LIF-STAT3 (Niwa et al., 1998), BMP4-Smad-Id (Ying et al.,
2003), or Wnt signaling (Sato et al., 2004). Instead, pluripotin
blocked two major differentiation-inducing pathways, i.e.,
MEK-ERK and Ras-GAP signaling (Johnson and Lapadat,
2002; Lypowy et al., 2005). This was significant because it
demonstrated the existence of a basal, self-renewing stem
cell state that can be maintained by inhibiting differentiation.ª2011 Elsevier Ltd All rights reserved 415
Table 1. Small Molecules for Self-Renewal in Stem Cells and iPSCs
Molecule Name Target Reference
Pluripotin/SC1
Dual inhibitor
RasGAP/ERK1
Chen et al. (2006)
CHIR99021 GSK3 inhibitor
Ying et al. (2008); Li et al.
(2009a), (2009b)
PD0325901 MEK inhibitor
Lin et al. (2009);
Zhu et al. (2010)
SU5402 FGF inhibitor Ying et al. (2008)
A-83-01 TGF-b inhibitor
Li et al. (2009a);
Zhu et al. (2010)
IQ-1
Phosphatase PP2A
inhibitor (Wnt modulator)
Miyabayashi et al. (2007)
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known pluripotency pathways. 6-Bromoindirubin-30-oxime
(BIO, Table 3), which activates the canonical Wnt signaling by
inhibiting GSK3, could maintain pluripotency in hESCs and
mESCs (Sato et al., 2004). However, this compound is strictly
a stabilizer of pluripotency signals and requires LIF to initiate plu-
ripotency. Another Wnt signal modulator called IQ-1 (Table 1)416 Chemistry & Biology 18, April 22, 2011 ª2011 Elsevier Ltd All rigcan replace exogenous LIF and feeder cell requirements in
mouse stem cell culture (Miyabayashi et al., 2007). Although
these studies suggest that Wnt signaling is a fundamental
component in regulating pluripotency, one must caution against
generalization because the role of any single signaling pathway
may be highly dependent on cellular context (Sato et al., 2004;
Dravid et al., 2005).hts reserved
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inducing signals, particularly the FGF/MEK-ERK pathway, has
proven to be highly effective for maintaining pluripotency of
ESCs. For example a cocktail of small molecule inhibitors,
dubbed ‘‘3i,’’ composed of GSK3 inhibitor CHIR99021 (Table 1),
MEK inhibitor PD0325901 (Table 1), and FGF receptor inhibitor
SU5402 (Table 1) added to the basal N2B27media effectively in-
hibited spontaneous differentiation and ensured homogeneous
Nanog expression, a key component for pluripotency mainte-
nance (Mitsui et al., 2003; Ying et al., 2008). A similar strategy
combining CHIR99021 (Table 1), PD0325901 (Table 1), and
TGF-b receptor inhibitor A-83-01 (Table 1) was also capable of
maintaining rat and human iPSCs (hiPSCs) (Li et al., 2009a).
Although significant progress has been made in under-
standing the basic mechanisms and characteristics of pluripo-
tency, current understanding is far from complete, and to
our knowledge, basal pluripotency requirements remain unde-
fined. Overcoming these obstacles through the discovery of
additional pluripotency pathways and their chemical modulators
could enable large-scale production of pluripotent cells and
finally provide a stable source of starting materials for tissue
regeneration.
Reprogramming
Major hurdles against the practical usage of iPSCs include low
reprogramming efficiency, and safety concerns raised by the
use of viral transduction in the process. The fast-moving pace
of the reprogramming and iPSC field has yielded numerous
reports of chemicals that either improve reprogramming
efficiency or can substitute for specific reprogramming factors.
Mechanistically, the chemicals generally function by altering
signal transduction pathways, or modify chromatin structure to
remove epigenetic barriers. These properties, when known, will
be described below.
Several small molecules improve the reprogramming process
by lowering the epigenetic barrier to initiate pluripotency. The
accompanying side effect is eliminating the need for one or
two Yamanaka factors (c-Myc or Sox2) in the reprogramming
cocktail. This is because those two factors are not necessary
to initiate pluripotency but are responsible for its maintenance
(Masui et al., 2007). These initial experiments focused on
mouse embryonic fibroblast (MEF) reprogramming. Valproic
acid (VPA, Table 2) is a histone deacetylase (HDAC) inhibitor
that dramatically improved reprogramming efficiency by 100-
fold without the use of c-Myc (Huangfu et al., 2008). A G9a
histone methyltransferase (HMTase) inhibitor, BIX01294
(Table 2), substantially increased reprogramming efficiency of
Sox2-expressing mouse neural progenitor cells (NPCs) trans-
duced with Oct4 and Klf4 (OK) to levels obtained with canonical
Yamanaka factors (Shi et al., 2008b). A similar example used
a combination of DNA methyltransferase (DNMT) inhibitor
called RG108 (Table 2), an L-type calcium channel agonist
called BayK8644 (Table 2), and BIX01294 to promote reprog-
ramming in MEFs transduced with OK (Shi et al., 2008a).
Another chemical screen identified a TGF-b signaling inhibitor
called RepSox (Table 2) as a potent Sox2 replacement
(Ichida et al., 2009). This molecule was shown to promote re-
programming by inducing Nanog expression, which is a tran-
scription factor known to drive self-renewal in ESCs (Pan and
Thomson, 2007).Chemistry & BThe chemical cocktails perfected in MEFs were quickly adap-
ted for human somatic cell reprogramming. A combination of
SB431542 (Table 2) and PD0323901 (Table 1), which inhibit
TGF-b and MAPK/ERK pathways, respectively, and thiazovivin,
which improves the survival of hESCs upon trypsinization,
increased reprogramming efficiency in human fibroblasts by
200-fold (Lin et al., 2009). The GSK3 inhibitor, CHIR99021
(Table 1), when combined with a lysine-specific demethylase 1
(LSD1) inhibitor called Parnate (also called tranylcypromine)
(Table 2), enhanced reprogramming of human keratinocytes
transduced with OK (Li et al., 2009b). A more recent report
described a stepwise chemical treatment protocol that required
only OCT4 transduction (Zhu et al., 2010). This protocol used
a combination of TGF-b receptor inhibitor A-83-01 (Table 1),
HDAC inhibitor sodium butyrate (NaB, Table 2), and PDK1
activator called PS48 (Table 2) for the first 4 weeks. For the
next 4 weeks, PD0323901 (Table 1) was combined with the
aforementioned mixture to complete reprogramming. The report
identified a switch in metabolic state from mitochondrial oxida-
tion to glycolysis, known in oncology as the ‘‘Warburg Effect’’
(Robey et al., 2008), which may be critical during reprogramming
(Zhu et al., 2010). The reprogramming efficiency using this
protocol was extremely low because only four to six iPSC
colonies formed for every 1 3 106 cells seeded (Zhu et al.,
2010). Nevertheless, this initial report demonstrates the power
chemical biology can hold for the future of human somatic cell
reprogramming.
There is another class of compounds that functions by dedif-
ferentiating lineage-committed cells to amore primitive, multipo-
tent state. Multiple studies have described reversine (Table 2) as
a potent dedifferentiation agent, which facilitated transformation
of differentiated cells to other lineages via a lineage-restricted
progenitor (Chen et al., 2004; Lee et al., 2009). Reversine was
characterized as an Aurora kinase inhibitor (D’Alise et al.,
2008), possibly specific for Aurora kinase B (Amabile et al.,
2009). Another Aurora kinase inhibitor, VX-608, was also found
to dedifferentiate mouse myoblasts (Amabile et al., 2009). The
partially reprogrammed state induced by these compounds
confirmed that cell fate commitment is a stepwise process,
and more importantly, some of the intermediate steps can be
manipulated chemically and may even be reversible.
These chemical biology studies suggest that somatic cells are
highly plastic and can be induced to assumemultiple dedifferen-
tiated states. This notion has parallels in the emerging concept of
distinct ‘‘naı¨ve’’ and ‘‘primed’’ pluripotent states, which has
gained serious consideration since the recent identification of
murine epiblast stem cells (EpiSCs) (Nichols and Smith, 2009).
EpiSCs derived from postimplantation epiblast represent
a more mature stage than mESCs, derived from the inner cell
mass of preimplantation blastocysts (Tesar et al., 2007; Bao
et al., 2009; Chou et al., 2008; Brons et al., 2007). EpiSCs
resemble hESCs in many ways, including their dependence on
bFGF/Activin A signaling instead of LIF/STAT signaling, flattened
colony morphology, their X-inactivation status, and their inability
to be passaged as single cells (Tesar et al., 2007; Brons et al.,
2007). These similarities suggest that hESCs are analogous to
the more mature, primed pluripotent state of EpiSCs. Recent
chemical biology studies demonstrated that EpiSCs, as well as
hESCs and hiPSCs, can be converted to the earlier, naiveiology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 417
Table 2. Small Molecules for Enhanced Reprogramming Efficiency
Molecule Name Target Reference
VPA HDAC inhibitor Huangfu et al. (2008)
BIX01294 A G9a HMTase inhibitor Shi et al. (2008b)
RG108 DNMT inhibitor Shi et al. (2008a)
BayK8644 L-type calcium channel agonist Shi et al. (2008a)
RepSox TGFb inhibitor Ichida et al. (2009)
SB431542 TGFb inhibitor
Lin et al. (2009);
Chambers et al. (2009)
Parnate LSD1 inhibitor Li et al. (2009a)
Sodium Butyrate (NaB) HDAC inhibitor Zhu et al. (2010)
418 Chemistry & Biology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved
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Table 2. Continued
Molecule Name Target Reference
PS48 PDK1 activator Zhu et al. (2010)
Reversine Aurora B kinase inhibitor
Chen et al. (2004);
D’Alise et al. (2008)
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scriptionally, and epigenetically similar to mESCs. Taking cues
from the 3i strategy described above, Ding and colleagues
(Zhou et al., 2010) successfully converted EpiSCs to the mESC
phenotype using a cocktail of small molecule inhibitors of
TGF-b receptor (A-83-01), FGF receptor (PD173074), MEK
(PD0325901), GSK3 (CHIR99021), and LSD1 (Parnate) added
to the LIF-containing media. Using a similar chemical biology
approach, Jaenisch and colleagues (Hanna et al., 2010) demon-
strated that the combination of three compounds PD173074,
CHIR99021, and forskolin, an activator of the enzyme adenylate
cyclase, added to the LIF-containing basal N2B27 media
induced the naive pluripotent state in both hESCs and hiPSCs.
Distinction between the naive and primed pluripotent states is
important because hiPSCs derived using current protocols are
thought to represent the latter, characterized by significant
biases in differentiation potential (Nichols and Smith, 2009).
Thus, conversion of hiPSCs to the naive pluripotent state may
be necessary for efficient generation of diverse patient-specific
tissues (Hanna et al., 2010).
The naive and primed pluripotent states have important impli-
cations for reprogramming and directed differentiation, espe-
cially in light of the recent discovery of the epigenetic memory
in iPSCs (Kim et al., 2010b; Ji et al., 2010). Epigenetic memory
is a phenomenon in which iPSCs derived from adult tissues
retain DNAmethylation signatures characteristic of their somatic
tissue of origin, unlike the classical ESCs. Furthermore, it may
sustain a residual gene expression signature from the parental
cell and account for gene expression differences between iPSCs
and ESCs (Ghosh et al., 2010; Chin et al., 2009). Consequently,
iPSCs preferentially differentiate along lineages related to the
parental cell, with restricted potential for alternative cell fates
(Kim et al., 2010b). Although the epigenetic memory of parental
tissues could at least partially be reset by treatment with chro-
matin-modifying drugs Trichostatin A (TSA), an inhibitor of
HDAC, and 5-azacytidine (AZA), a cytosine analog resistant to
methylation (Kim et al., 2010b), it represents a significant barrier
against full reprogramming and directed differentiation toward
many desired cell types.Chemistry & BThere are now many examples of chemical modulators facili-
tating cellular reprogramming by increasing reprogramming
efficiency, eliminating potentially oncogenic factors in the
reprogramming cocktail, or increasing cell fate plasticity. These
observations have also fueled new questions and challenges.
In most cases the precise mechanisms by which synthetic
chemicals influence reprogramming are yet to be discovered.
Additional chemical biology advances are needed to completely
erase epigenetic memory and to eliminate the need for exoge-
nous reprogramming factors altogether. Given tremendous
advances in the past few years, we anticipate that future devel-
opments will substantially improve the process of iPSC genera-
tion and provide better understanding of reprogramming.
Directed Differentiation
Achieving and maintaining a pluripotent stem cell population is
one element in regenerative therapy improvement. Another
requirement is to produce large quantities of stage-specific cells
in a controlled manner in vivo. A pluripotent cell population
cannot be used directly in patients because it can form tumors.
Therefore, it is necessary to predifferentiate pluripotent cells to
a desired cell type prior to transplantation. Compounds for this
purpose have been identified in high-throughput assays based
on lineage-specific gene expression profiles (Figure 2), and will
be discussed below in relations to the three germ layers: endo-
derm, mesoderm, and ectoderm. The net effects of these chem-
icals have been to functionally promote lineage commitment or
to block self-renewal maintenance and spur differentiation.
The endoderm lineage has been the least characterized of the
three lineages due to the lack of early endoderm markers, but
imperfect markers, like Sox17 and Foxa2, exist for later endo-
derm commitment (Iwamuro et al., 2010). Two chemical
compounds named IDE1 (Table 3) and IDE2 were identified
from a library of putative HDAC inhibitors based on Sox17 induc-
tion (Borowiak et al., 2009). IDE1 and IDE2 activated close to
80% endoderm progenitor production in mouse and human
stem cells, which is above that of known TGF-b modulators
Activin A and Nodal (Borowiak et al., 2009). The compounds
upregulated Nodal signaling, and increased endoderm lineage
commitment and developmental competence (Borowiak et al.,iology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 419
Table 3. Small Molecules for Directed Differentiation
Molecule Name Target Reference
IDE1 Unknown Borowiak et al. (2009)
ILV PKC activator
Borowiak et al. (2009);
Chen et al. (2009)
Cardiogenol C Unknown Wu et al. (2004)
Dorsomorphin
BMP type 1
receptor inhibitor Hao et al. (2008)
BIO GSK3 inhibitor (Wnt activator)
Sato et al. (2004);
Naito et al. (2006);
Tseng et al. (2006);
Qyang et al. (2007)
Neuropathiazol Unknown Warashina et al. (2006)
SB216763 GSK3 inhibitor (Wnt activator) Lange et al. (2011)
Kenpaullone GSK3 inhibitor (Wnt activator) Lange et al. (2011)
KHS101 TACC3 (mitotic spindle) Wurdak et al. (2010)
Stauprimide NME2 (metastatic factor) Zhu et al. (2009)
420 Chemistry & Biology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved
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increased development of Pdx-1 expressing pancreatic progen-
itors from endoderm-biased progenitors (Borowiak et al., 2009;
Chen et al., 2009). Proliferation studies showed that ILV did not
drive proliferation of existing Pdx-1 expressing cells but, rather,
committed other cell types of the heterogeneous endoderm-
restricted pool toward the pancreatic progenitor lineage via
activation of protein kinase C (PKC) (Chen et al., 2009). However,
there was no mechanism proposed on how PKC activation
increases pancreatic progenitors.
Similarly, there are examples of chemical cocktails that direct
mesoderm-lineage commitment. However, to our knowledge,
the mechanisms are unknown. Cardiogenol C (Table 3) was
identified in a high-throughput, cardiac-specific ANF reporter
assay (Wu et al., 2004). It specifically induces cardiomyocyte
formation in mESC culture after 3 days of treatment (Wu et al.,
2004). However, the compound appears to only be effective in
certain cell types (Jasmin et al., 2010), which would suggest
that it is a nonspecific compound that requires a specific cellular
context to support procardiac effects.
Modulation of BMP signaling can direct ectoderm and meso-
derm formation during embryonic differentiation (Winnier et al.,
1995; Finley et al., 1999). A BMP selective inhibitor identified
using an unbiased, high-throughput in vivo screen in zebrafish,
called dorsomorphin (Table 3), induced beating cardiomyocyte
formation in mESC culture (Yu et al., 2008; Hao et al., 2008).
Unlike cardiogenol C, dorsomorphin is required only during the
first 24 hr of induction to specify cardiomyocyte commitment.
This time frame makes the procardiomyogenic mechanism of
dorsomorphin especially interesting because it occurs prior to
the expression of known early mesoderm markers like BryT
andMesp1 (Kubo et al., 2004; Bondue et al., 2008). This strongly
suggests that dorsomorphin increases cardiomyogenesis by
way of an unknown progenitor.
Chemical modulation of the Wnt signaling also has profound
effects on mesoderm specification and cardiomyocyte induc-
tion. GSK3 inhibitor BIO (Table 3), which activates Wnt
signaling, significantly induced cardiomyocyte formation in
mESCs when introduced during the first 3 days of ESC differen-
tiation (Naito et al., 2006). BIO was also reported to markedly
expand the specific subset of ESC-derived embryonic and
postnatal cardiovascular progenitor cells that express the Isl1
marker (Qyang et al., 2007). These results outlined the stage-
specific role of Wnt signaling in cardiac progenitor specification
and proliferation. Paradoxically, cardiomyocyte differentiation
was suppressed when mESCs were exposed to BIO after day
5 of differentiation, following the formation of cardiovascular
progenitor cells (Naito et al., 2006). A similar biphasic role of
Wnt signaling was demonstrated in hESCs (Paige et al., 2010),
whereby inhibiting Wnt signaling in multipotent mesodermal
progenitor cells promoted cardiac differentiation (Kattman
et al., 2011). Consistent with these results, XAV939, a selective
small molecule inhibitor of Tankyrase required for Wnt signaling,
markedly induced cardiomyogenesis in mESCs when intro-
duced after mesoderm formation (Wang et al., 2011). In
summary these studies suggest that stage-specific chemical
modulation of Wnt signaling is a promising strategy for directed
differentiation of cardiac cell types in human pluripotent stem
cells.Chemistry & BIn contrast to the endoderm and mesoderm lineages, ecto-
derm differentiation of ESCs is commonly considered a default
developmental pathway (Reubinoff et al., 2000). Ectoderm
commitment can be further promoted by inhibiting BMP (Winnier
et al., 1995; Finley et al., 1999) and downstream SMAD signaling
(Sirard et al., 1998) that are required for mesoderm formation
(Finley et al., 1999). This signaling pathway can be targeted using
chemical means in conjunction with other protein modulators.
The TGF-b inhibitor SB431542 (Table 2), when used in combina-
tion with BMP inhibitor Noggin, induced neural differentiation in
hESC and hiPSC (Chambers et al., 2009). There are other
compounds that can generate the neurogenic phenotype, but
the mechanism is not well characterized. Neuropathiazol
(Table 3) can induce differentiation of human hippocampus
progenitors into neurons (Warashina et al., 2006), which may
hold therapeutic potential as a treatment for Parkinson’s
disease. An additional proneurogenesis cocktail was described
recently: GSK3 inhibitors SB216763 and kenpaullone (Table 3)
were found to stimulate human NPCs’ commitment by upregu-
lating Wnt signaling without changing cell cycle progression or
proliferation (Lange et al., 2011). This observation would suggest
that the neurogenic effect of SB216763 and kenpaullone may be
to increase lineage commitment rather than to expand existing
neural cells.
A study performed in rats showed that the compound KHS101
(Table 3) can induce neural differentiation by inhibiting NPC
maintenance, while also stabilizing proneurogenesis transcrip-
tional pathways (Wurdak et al., 2010). KHS101 was shown to
negatively affect cell cycle exit and proliferation, thereby block-
ing the maintenance of the undifferentiated NPC phenotype.
Concurrently, KHS101 physically interacted with TACC3
(a structural component of the centrosome and mitotic spindle)
and prevents its ability to sequester ARNT2 (a proneurogenesis
transcription factor) in the cytoplasm (Wurdak et al., 2010). The
net effect was that KHS101 accelerated neural differentiation
from the progenitor pool by blocking self-renewal.
It would be extremely useful if protein modulators could be
excluded completely from the cell fate decision process, and
stepwise lineage commitment was achieved chemically. In the
event that such compounds or protocols failed to arise, ESCs
can be chemically manipulated to increase their sensitivity to
exogenous differentiation signals. Stauprimide (Table 3) was
reported to prime mESCs and hESCs for differentiation via
interaction with NME2, a metastatic factor with a possible
role in promoting pluripotency (Zhu et al., 2009). The initial
report did not demonstrate that the compound stimulates
differentiation toward any particular lineage but, rather,
amplifies induction efficiency (Zhu et al., 2009). The mechanism
is unclear at this time, but it may be that NME2 inhibition limits
self-renewal maintenance by reducing c-Myc expression (Tha-
kur et al., 2009). In this case, stauprimide may function by
making self-renewal an unfavorable condition for the cell and,
thus, lowering the energy requirements for extracellular differ-
entiation signals. It would be interesting to see whether modu-
lating self-renewal can be a general approach to promote
directed differentiation.
The above examples introduced some of the potential advan-
tages of using small molecules for directed differentiation. Not
only do they help uncover novel differentiation mechanismsiology 18, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 421
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Reviewand interact with known development pathways, but they also
offer fine temporal control to the investigator. Given our limited
knowledge of the temporal regulation of individual pathways,
chemical biology has yielded intriguing insights into the dynamic
interactions that drive cell fate commitment, and continues to be
integrated with developmental and cellular biology. The foresee-
able trajectory for all these areas is to promote basic under-
standing of developmental mechanisms and to apply this
knowledge toward improving clinical outcomes.
The Future of Bioactive Compounds
in Cell-Based Therapy
An emerging area of interest for both regenerative medicine and
chemical biology is the manipulation of the local tissue microen-
vironment following transplantation. Transplanted cells are
generally introduced to a hostile environment in injured or
diseased tissues, resulting in massive cell loss and depleting
much of their therapeutic potential. Identification of signaling
pathways that improve the survival of newly introduced cells
either by inhibiting apoptosis or sustaining proliferation would
be of special interest. In addition, transplanted cells will likely
require extracellular cues to fully mature and undertake their
functional role in regeneration or repair. Therefore, under-
standing and controlling these extracellular factors are required
to extract long-term benefits from any cell-based system.
A paradigm shift has occurred in regenerative medicine that
will require a multifaceted approach to cell-based therapies. It
would require focus not only on robust pluripotency mainte-
nance and appropriate cell differentiation, but also on their inter-
actions with the extracellular milieu. The future of this field will
require a fully coordinated view that will match specific pluripo-
tent/progenitor states to the desired differentiated population,
and their incorporation into the optimal extracellular support
matrices for downstream applications. At this point, the usage
of bioactive compounds is in the early stages, and questions
remain concerning their cellular properties compared to that
produced by natural processes. Additional studies are required
to better correlate in vitro benefits to in vivo applications as
well as their pharmacological properties. Nevertheless, small
molecules have shown themselves as enablers of regenerative
therapy and have reduced many of its challenges. They will
undoubtedly play a critical role in many areas of stem cell
research and helpmobilize those discoveries toward therapeutic
options.
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